ReviewiScience2026
The role of serologic biomarkers "liquid biopsy" in the fight against breast cancer: From biological foundations to clinical impact.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liquid biopsy, analyzing circulating tumor-derived components, including ctDNA, circulating tumor cells, microRNAs, and exosomes, has emerged as a key tool in precision oncology. This review synthesizes evidence from the past five years, covering biological mechanisms, analytical platforms, clinical applications, and implementation barriers. Evidence from multiple clinical studies suggests ctDNA shows higher sensitivity for metastatic disease monitoring than conventional biomarkers such as CA15-3 and circulating tumor cells. For minimal residual disease detection, tumor-informed assays demonstrate sensitivity of 88%-100% and provide a median lead time of 8-15 months before clinical relapse. Despite these advances, early-stage cancer detection remains suboptimal, cost-effectiveness evidence is limited, and disparities in access are increasing. We critically evaluate current technologies and translational gaps and highlight the need for standardized clinical integration pathways. Overall, liquid biopsy is transitioning from a complementary diagnostic tool toward a longitudinal framework for cancer management, although substantial methodological and systemic challenges remain.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.